/ /

  • linkedin
  • Increase Font
  • Sharebar

    Neuroprotective drug need not be an impossible dream


    The CSFI is considerably more sensitive than mean deviation, visual field index, and OCT average thickness for detecting progressive glaucomatous damage [Am J Ophthalmol. 2012;154:814-24].

    Looking to the future, Dr. Weinreb proposed two indications for a neuroprotective drug for glaucoma. One use would serve as complementary therapy, where the agent is added to medical treatment or used after surgery in patients who achieve IOP-lowering, but are still experiencing progressive loss of visual function. The second would serve as an alternative therapy for patients in whom IOP-lowering agents are not tolerated or ineffective.

    “I am optimistic that we have a pathway forward and there is an opportunity to bring neuroprotection therapy to glaucoma management,” Dr. Weinreb said.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results